ExSight Ventures

347 posts

ExSight Ventures banner
ExSight Ventures

ExSight Ventures

@ExsightV

We are a venture capital firm specializing in early-stage investments in innovative ophthalmic diagnostic and treatment solutions.

New York, NY Присоединился Ağustos 2018
227 Подписки116 Подписчики
Закреплённый твит
ExSight Ventures
ExSight Ventures@ExsightV·
ExSight partners Firas and James discussing early stage funding of ophthalmic innovation @ OIS Retina with @ONLTherapeutics CEO David Esposito and our friends from InFocus and Outlook Tx. @OISTWEETS
ExSight Ventures tweet media
English
0
1
9
0
ExSight Ventures ретвитнул
Elios
Elios@elios_vision·
Dr. @ikekahmed and Professor @gusgazzard kick off the Interventional Glaucoma podcast series as co-hosts with an unscripted discussion about the evolving mindset of interventional glaucoma. They explore the motivations behind this shift, including the need to address the limitations of current treatments, and highlight cataract surgery as an opportune entry point to intervene with simultaneous glaucoma treatment. Listen now on Apple, Spotify and YouTube. eliosvision.com/ous/podcast/ #EliosVision #Glaucoma #Elios #Excimerlaser #Ophthalmology eliosvision.com/disclaimer ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.
Elios tweet media
English
0
2
3
760
ExSight Ventures ретвитнул
Elios
Elios@elios_vision·
Elios Vision is honored to have Prof. @ikekahmed as co-host for the first episode of the Interventional Glaucoma Podcast. Professor Ahmed is a world-renowned glaucoma, cataract, and anterior segment surgeon, with a practice focus on the surgical management of glaucoma, complex cataract and intraocular lens complications. He is board certified in ophthalmology in Canada and the USA, and is an active member of numerous national and international societies. Listen now on Apple, Spotify and YouTube. eliosvision.com/ous/podcast/ #EliosVision #Glaucoma #Elios #Excimerlaser #Ophthalmology eliosvision.com/disclaimer ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.
English
0
1
1
60
ExSight Ventures
ExSight Ventures@ExsightV·
We've been sharing our excellent experience with Squared Away. This profile of the founder tells a great entrepreneurial journey and speaks to why you should be considering contacting them if you need a personal assistant.
Squared Away@gosquaredaway

"Military spouse Michelle Penczak got tired of getting turned down for jobs, so she did something about it. Now she runs a $5 million company that helps women just like her." @michellepencz @kelseyopel & co-founder @ShaneMac #squaredawaylife #startup saturdayeveningpost.com/2021/06/one-wo…

English
0
0
1
106
ExSight Ventures
ExSight Ventures@ExsightV·
Yosemite is an important model for funding early stage innovation. Focusing on the the early stage while simultaneously funding charitable grants for scientists and labs will raise the quality of startups focused on cancer. 👏 @EmCollective biopharmadive.com/news/yosemite-…
English
1
0
1
58
ExSight Ventures
ExSight Ventures@ExsightV·
Congratulations to the team at DTx Pharma on this amazing achievement!
English
0
0
2
334
ExSight Ventures
ExSight Ventures@ExsightV·
LPs often ask what we look for in evaluating companies. This response from legendary pharma founder and scientist is spot on: "The most important thing is understanding team dynamics and the difference in personalities that are necessary to build a team and hold it together."
Angelos Georgakis@angelosgeo

The founder and former CEO of Vertex Pharmaceuticals, Joshua Boger, was once asked: "What does it take to be a good leader in a pharmaceutical company?" Boger said, "Pharmaceutical discovery and development is the most complicated activity that humans do. Going to Mars is easy, going to Mars is engineering! I mean, I'm not an engineer but if you give me a hundred billion dollars, I guarantee you I can put you on Mars. There's nothing stopping me except organisational momentum and money. But if you give me a hundred billion dollars and say, in five years or ten years you have to cure Alzheimer's disease... I'll say... I'll give it a go but I have no idea whether I could do it! Drug discovery and development is just an insanely complicated activity to do that you need to keep teams of people together for a very long time. And this is what distinguishes it from most of the high-tech, ie. I have a high-tech idea, I should be shipping it in 18 months. If I have a pharmaceutical idea I may be shipping it in 18 years! So I need to keep a team of people together on the discovery and development side for 12 to 15 years on average. The most important thing is understanding team dynamics and the difference in personalities that are necessary to build a team and hold it together. To do that, you the leader have to be incredibly passionate about what you're trying to do. It's a combination of empathy and passion... And you have to lead by example. Very often I was the last person to cut the lights out at midnight or 1 am. And it's not just the number of hours... the people who report to you can see you, and they can tell whether or not you're thinking about the mission all the time..."

English
0
0
3
200
ExSight Ventures ретвитнул
Elios
Elios@elios_vision·
Check out our highlights from Day 1 at the WGC! It has been great connecting with everyone. Bring on Day 2! #WGC #Elios #disclaimer" target="_blank" rel="nofollow noopener">eliosvision.com/#disclaimer ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.
Elios tweet mediaElios tweet mediaElios tweet mediaElios tweet media
English
0
1
2
485
ExSight Ventures
ExSight Ventures@ExsightV·
Roman Holiday - @elios_vision heads to the eternal city for the World Glaucoma Congress.
Elios@elios_vision

We are attending the WGC on 28th June – 1st July. Join us at our booth and look out for our ‘What the hELIOS’ symposium! #WGC #Elios #disclaimer" target="_blank" rel="nofollow noopener">eliosvision.com/#disclaimer ELIOS is not approved for sale in the United States, where it is limited by Federal law to investigational use.

English
0
0
1
58
ExSight Ventures ретвитнул
BowTiedBiotech 🧪🔬🧬
BowTiedBiotech 🧪🔬🧬@BowTiedBiotech·
May #Biotech Hedge Fund Performance RA Cap +7.8% (+1.2% YTD) Casdin +4.7% (+10.7% YTD) Soleus +4.4% (+3.4% YTD) Perceptive +2.4% (+8.4% YTD) RTW +1.8% (+6.4% YTD) Averill +1.5% (+2.6% YTD) XBI +3% (+5.6% YTD)
Suomi
0
7
55
30.7K
ExSight Ventures ретвитнул
ASCRS
ASCRS@ASCRStweets·
Cataract misconception: Cataract surgery is an “easy” procedure. Learn more bit.ly/3M9kktK #CataractAwareness
ASCRS tweet media
English
0
3
7
1K
ExSight Ventures ретвитнул
Brian McCaul
Brian McCaul@brianamc·
In Northern Ireland there were also five deals in 2022 into life sciences, one of which was valued at £9.9m into Re-Vana Tx @TxVana, a spin-out from Queen’s University which is developing technologies for photocrosslinking for ocular drug delivery @QubisLtd
Brian McCaul@brianamc

University spin-outs ...received 12% of total equity investment in 2022, at a value of £2bn. The ave. deal size for university spinouts was £8.9m, 33% higher than the wider market. Out of the 34 deals in N. Ireland, 9 were Queen's University spin-outs. insidermedia.com/news/ireland/r…

English
1
4
7
771
ExSight Ventures ретвитнул
lensgeninc
lensgeninc@lensgeninc·
Sumit Garg, M.D. Presented Thirty-Six Months Grail Study Visual Outcomes at the American Society of Cataract and Refractive Surgery Conference lensgen.com/sumit-garg-m-d…
English
0
1
2
43
ExSight Ventures
ExSight Ventures@ExsightV·
ExSight portfolio company @TrefoilThera was featured in their hometown San Diego Business Journal “We’re happy because the drug works. We demonstrated that it works.” - David Eveleth Read the article here: lnkd.in/gJZv5ytb @SDbusiness
English
0
0
3
75
ExSight Ventures
ExSight Ventures@ExsightV·
For Clinical Trials Day 2023 @ONLTherapeutics hosted investigators of their Ph 2 clinical trial studying ONL1204 Ophthalmic Solution in retinal detachment patients. Thank you to all participating clinicians, research staff, and patients. linkedin.com/feed/update/ur…
English
0
1
0
37